Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Poolbeg Pharma "couldn't be happier" with POLB 001 human challenge trial data

By: TheNewswire.com
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing the data readout from an LPS human challenge trial for POLB 001, the infectious disease focused biopharma company's lead molecule.

Skillington says that he "couldn't be happier" with the results, that he says will help "ramp up the discussions" with potential partners.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  234.11
+1.32 (0.57%)
AAPL  294.30
-2.71 (-0.91%)
AMD  519.85
-31.78 (-5.76%)
BAC  57.91
+0.54 (0.94%)
GOOG  346.08
-2.70 (-0.77%)
META  562.20
-1.65 (-0.29%)
MSFT  373.94
+6.60 (1.80%)
NVDA  200.04
-8.61 (-4.13%)
ORCL  165.16
-9.91 (-5.66%)
TSLA  381.61
-23.44 (-5.79%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>